GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CanSino Biologics Inc (HKSE:06185) » Definitions » Total Current Liabilities

CanSino Biologics (HKSE:06185) Total Current Liabilities : HK$2,284.2 Mil (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is CanSino Biologics Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. CanSino Biologics's total current liabilities for the quarter that ended in Mar. 2024 was HK$2,284.2

CanSino Biologics Total Current Liabilities Historical Data

The historical data trend for CanSino Biologics's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CanSino Biologics Total Current Liabilities Chart

CanSino Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Current Liabilities
Get a 7-Day Free Trial 138.31 489.41 3,520.27 3,285.45 2,834.90

CanSino Biologics Quarterly Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 2,992.80 2,644.74 2,834.90 2,284.24

CanSino Biologics Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

CanSino Biologics's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=1052.499+1596.368
+Other Current Liabilities+Current Deferred Liabilities
=186.037+0
=2,834.9

CanSino Biologics's Total Current Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=645.981+1037.445
+Other Current Liabilities+Current Deferred Liabilities
=600.81+0
=2,284.2

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

CanSino Biologics Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of CanSino Biologics's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

CanSino Biologics (HKSE:06185) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CanSino Biologics Inc (HKSE:06185) » Definitions » Total Current Liabilities
Comparable Companies
HKSE:02005 HKSE:03933 HKSE:00512 HKSE:03613 HKSE:01349 HKSE:02096 HKSE:01558 HKSE:00570 HKSE:06600 HKSE:00460 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
CASBF:USA CJH:Germany 688185:China
Address
185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, CHN
Website
https://www.cansinotech.com
CanSino Biologics Inc is a China-based company engaged in the research and development, manufacturing and commercialization of vaccine products for human use. These include products such as pneumococcal polysaccharide and conjugate vaccines as well as a DTcP-based combo and other items. At the same time, the group is also dedicated to the development of new vaccine-like recombinant adenovirus vector-based tuberculosis vaccines and a recombinant protein-based pneumococcal vaccine. Geographically, the activities are carried out through China.
Executives
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you
Jpmorgan Chase & Co.
Citigroup Inc.
The Goldman Sachs Group, Inc. 2201 Interest of corporation controlled by you
Blackrock, Inc. 2201 Interest of corporation controlled by you
Mao Helen Huihua 2201 Interest of corporation controlled by you
Qiming Corporate Gp Iv, Ltd. 2201 Interest of corporation controlled by you
Qiming Gp Iv, L.p. 2201 Interest of corporation controlled by you
Qiming Venture Partners Iv, L.p. 2201 Interest of corporation controlled by you
Qm29 Limited 2101 Beneficial owner
Qiu Dongxu 2501 Other
Yu Xuefeng 2501 Other
Zhu Tao
Chao Shou Bai 2202 Interest of your spouse
Orbimed Capital Llc 2102 Investment manager

CanSino Biologics (HKSE:06185) Headlines

No Headlines